Anebulo Pharmaceuticals Aktie

Anebulo Pharmaceuticals' stock fell 36.6% after the company announced a voluntary delisting from the Nasdaq Capital Market and deregulatory filing with the SEC. The board said the costs and burdens of SEC and NASDAQ reporting obligations outweigh the benefits, even though listing requirements are met. Anebulo expects to file a Form 25 around Feb. 17, 2026, making the delisting effective on Feb. 27, and to file a Form 15 thereafter, which would suspend regular SEC reporting. After the delisting, trading is likely to be limited to over-the-counter and privately negotiated transactions, significantly reducing liquidity for shareholders, while management intends to focus on further developing its lead product candidate. » Más en de.investing.com

Anebulo has completed the voluntary buyback offer, in which about 4.9 million shares were tendered and the company will acquire 300,000 common shares at $3.50 per share. Due to strong oversubscription, acceptance is provisional on a pro rata basis with an allocation factor of roughly 3.52%; odd‑lot tenders will be fully accepted. The repurchases equal about 0.73% of outstanding shares and will cost Anebulo roughly $1.05 million before fees; the stock trades at $1.08 and the company reportedly has more cash than debt. Anebulo continues developing Selonabant and is examining an intravenous formulation for pediatric cases of acute cannabis intoxication. » Más en de.investing.com

Anebulo has treated the first subjects in a randomized, double‑blind phase‑1 study of ascending single doses of the intravenously administered CB1 antagonist Selonabant. The study in healthy 18‑ to 25‑year‑olds is supported by NIDA funding and examines safety, tolerability and pharmacokinetics; intravenous development is being prioritized for pediatric emergencies. Anebulo previously tested an oral formulation in phase‑2 and is now exploring strategic alternatives, including a possible delisting via share consolidation; the company is currently loss‑making but, according to analysis, has cash exceeding liabilities and a market capitalization of around $101 million, and the stock rose by more than 60% in six months. » Más en de.investing.com